QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced Thursday the acquisition of the remaining 80.1% of diagnostics instruments company NeuMoDx Molecular, Inc. for $248 million in cash. The move rounds out QIAGEN’s portfolio of automated molecular testing solutions based on the proven PCR technology. The transaction was completed after QIAGEN received U.S. regulatory clearance for the full acquisition. In 2018, QIAGEN had purchased a 19.9% stake in NeuMoDx along with the right to acquire the remaining NeuMoDx stake at a price of $234 million. The final payment price for this remaining stake includes customary purchase price adjustments for cash, indebtedness and transaction costs.
Read the full article: QIAGEN Fully Acquires NeuMoDx Molecular, Inc., Rounding Out Portfolio of PCR-Based Diagnostic Automation Systems //
Source: https://www.businesswire.com/news/home/20200917005682/en/QIAGEN-fully-acquires-NeuMoDx-Molecular-Inc.-rounding-out-portfolio-of-PCR-based-diagnostic-automation-systems